SYNTEX SELLING DENTAL BUSINESS TO DEN-TAL-EZ DENTAL PRODUCTS
SYNTEX SELLING DENTAL BUSINESS TO DEN-TAL-EZ DENTAL PRODUCTS Corporation for an undisclosed amount. Den-Tal-Ez is a newly formed corporation controlled by Raymond Perelman, a private investor with interests in dental equipment manufacturer Chayes Virginia and a number of other manufacturing businesses. The sale of 100% of the stock of the Syntex dental subsidiary -- which had volume of approximately $50 mil. the past several years -- is "expected to close during late October, following review by the Federal Trade Commission," Syntex said Sept. 15. The businesses being sold include Den-Tal-Ez, which manufactures dental operatory equipment; Custom Vac, which manufactures custom vacuum equipment for the dental office; Star Dental, which makes dental hand pieces and related equipment; and Columbia Dentoform, which makes model jaws and teeth for dental education and training. Syntex' dental products business had an operating loss of $1.6 mil. on sales of $49.3 mil. in fiscal 1985, down 11% from the previous year. The division's volume has been declining since 1981 when sales of nearly $60 mil. were generated. Syntex blamed the sales decline in 1985 on a decrease in demand for the company's large dental equipment, such as chairs and modular cabinetry. The agreement for the sale of the dental business to the new Den-Tal-Ez Corporation comes six weeks after Syntex announced that it was putting the division up for auction. According to its recently released quarterly report, the company recorded a 33% fourth quarter slide in net income to $28.9 mil., resulting from a $23 mil. loss on the anticipated sale of its dental operations. Syntex said the sale "will not have any further financial impact" on the company.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth